Publication Name	World Journal of Hepatology
Manuscript ID	36209
Country	Italy

Category	Gastroenterology & Hepatology
Manuscript Type	Observational Study
Article Title	Outcomes assessment of hepatitis C virus-positive psoriatic patients treated using pegylated interferon in combination with ribavirin compared to new Direct-Acting Antiviral agents
Manuscript Source	Invited Manuscript
All Author List	Giovanni Damiani, Chiara Franchi, Paolo Pigatto, Andrea Altomare, Alessia Pacifico, Stephen Petrou, Sebastiano Leone, Maria Caterina Pace and Marco Fiore
Funding Agency and Grant Number
Corresponding Author	Marco Fiore, MD, Doctor, Department of Anesthesiological, Surgical and Emergency Sciences, University of Campania “Luigi Vanvitelli”, Piazza Miraglia 2, Naples 80138, Italy. marco.fiore@hotmail.it
Key Words	Hepatitis C virus; New Direct-Acting Antiviral agents; Psoriasis; Biological disease modifying drugs
Core Tip	Psoriasis is a chronic inflammatory disease affecting approximately the 2% of population in Europe and North America. The hepatitis C virus (HCV) infection affects approximately the 3% of the world population with an estimated prevalence of 5 million people in the United States. Up to 0.06% of people in the United States suffer from both psoriasis and HCV. Psoriatic patients with HCV are excluded by randomized controlled clinical trials. Therefore, no data is currently available concerning the concomitant administration of biological disease modifying drugs and the new Direct-Acting Antiviral agents (DAAs) medications approved for the treatment of HCV infection. The aim of this study is to evaluate the outcomes in biological treatment and quality of life of psoriatic patients with HCV infection treated with DAAs compared to the previous standard therapy of Pegylated Interferon plus Ribavirin.
Citation	Damiani G, Franchi C, Pigatto P, Altomare A, Pacifico A, Petrou S, Leone S, Pace MC, Fiore M. Outcomes assessment of hepatitis C virus-positive psoriatic patients treated using pegylated interferon in combination with ribavirin compared to new Direct-Acting Antiviral agents. World J Hepatol 2018; 10(2): 329-336

Received	2017-11-28 02:40
Peer-Review Started	2017-11-28 07:57
To Make the First Decision	2017-12-11 08:18
Return for Revision	2017-12-13 09:08
Revised	2017-12-18 21:40
Second Decision	2018-01-16 06:39
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2018-01-24 05:10
Articles in Press	2018-01-24 05:10
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2018-02-24 03:09

ISSN	1948-5182 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com